Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead withdraws bladder cancer drug in US
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year.
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a primary completion date in January 2027.
Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval in that indication.
Drugmaker Pulls Trodelvy's Bladder Cancer Approval
Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made in consultation with the FDA and does not affect the antibody-drug conjugate's other indications,
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact Trodelvy's other approved uses.
Gilead withdraws bladder cancer drug Trodelvy in US
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S.
ENDPOINTS NEWS
1d
Gilead pulls Trodelvy's accelerated label in bladder cancer after drug failed confirmatory study
Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
pharmaphorum
1d
Gilead's Trodelvy approved in metastatic urothelial cancer
have been withdrawn in
bladder
cancer
as a result.
Gilead
said Trodelvy’s safety profile in the TROPHY study is consistent with previous observations in metastatic UC and other tumour types.
Business Wire
11h
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Advance to World Series
Reaches tentative union deal
Ferry dock collapses in GA
Boat rider arrested in FL
Republicans appeal ruling
NYC Halloween dog parade
US probing documents leak
MS after game shooting
School shooting report
Postpones US tour
Hurricane Oscar forms
Orionids meteor shower
US deficit reaches $1.8T
Philip Zimbardo dies at 91
To furlough 700 workers
NK sending troops to RU?
$4M LAPD fentanyl seizure
Probes near miss in Austin
At decade-high level
Opioid suits settlement deal
Ex-MN congressman dies
Bladder cancer drug pulled
Antitrust ruling delayed
Challenges military listing
Emergency abortion ruling
Calif. oil refinery closure
G7 ministers back Ukraine
Frozen waffles recalled
Fire prompts evacuations
NC breaks turnout record
Feedback